4-Butylresorcinol vs 4-Hexylresorcinol

Quick Answer

4-Butylresorcinol (4BR) and 4-Hexylresorcinol (4HR) are related resorcinol derivatives, but they are not interchangeable grades of the same raw material. They have different chemical identities, molecular weights, evidence bases, supplier ecosystems and formulation implications. A buyer deciding between them should first define the product job: a pigment-focused active with a comparatively specific clinical history, a broader multifunctional brightening system, or a delivery format where solvent and compatibility risk are the main constraints. The evidence supports a structured comparison, not a blanket winner.

First Remove the Identity Error

4BR means 4-n-butylresorcinol, CAS 18979-61-8, molecular formula C10H14O2 and molecular weight 166.22. 4HR means 4-hexylresorcinol, CAS 136-77-6, molecular formula C12H18O2 and molecular weight 194.27. The extra carbon units in 4HR are not a cosmetic naming detail. They change the molecule’s physical behavior and mean that assay, molecular-weight conversions, impurity profiles and safety documentation must remain compound-specific.

Marketplace titles can use “resorcinol,” “butylresorcinol,” “hexylresorcinol” and trade names inconsistently. A document that shows the wrong CAS should be held for clarification. Do not accept a supplier’s statement that the materials are “similar” as a substitute for identity confirmation.

What the Comparative Evidence Actually Shows

The most directly relevant comparison located in the literature is the work reported by Kolbe and colleagues. In an in-vitro comparison, 4BR showed stronger inhibition of human tyrosinase than the comparator derivatives tested. A separate topical age-spot study compared formulas containing 4BR, 4HR and phenylethylresorcinol; the paper reported greater visible improvement with the 4BR formula under that study design.

That is meaningful evidence for 4BR in the tested context, but it is not proof that every 4BR raw material, concentration or finished formula will outperform every 4HR system. The comparison was not a universal head-to-head benchmark across identical modern delivery systems, suppliers and packages. A result observed with one vehicle does not automatically transfer to a water serum, emulsion, liposome or blend containing several pigment-modulating ingredients. Nor does an in-vitro potency value predict finished-product tolerability or consumer adherence.

4BR also has human-use evidence rather than merely a mechanistic claim. A randomized split-face study evaluated a 0.1% 4BR cream for melasma, and other clinical work has examined higher-concentration systems. Those studies support a defined human-use evidence base for 4BR. They do not establish that 4HR should be dosed at the same percentage or that the two ingredients can be swapped without reformulation.

A Buyer-Side Comparison Matrix

Why “More Potent” Does Not Settle the Formulation Choice

The commercial decision is made in a finished product, not in an isolated enzyme assay. A raw material that appears stronger in one test can lose practical value if it is difficult to dissolve, destabilizes during cooling, discolors in the selected package or forces a solvent load that compromises skin feel and preservation.

Conversely, a less compelling headline potency result may still be useful if the supplier can provide a reproducible delivery format, stable emulsion and credible finished-formula data. For 4BR, recent formulation research has focused on nanoemulsions and other delivery approaches because poor solubility and stability can constrain straightforward use.[1]

This does not mean every encapsulated 4BR is superior to neat 4BR. It means the buyer should compare active loading, assay after processing, particle or dispersion data where relevant and stability under the actual package. The same discipline should be applied to any 4HR product promoted as “easy to formulate.”

How to Compare Percentages Without Creating a False Equivalence

A percentage is meaningful only when the compound, basis and formula are clear. Do not treat 0.3% 4BR as a direct equivalent of 0.3% 4HR, and do not use a supplier’s suggested use range as evidence that the same range applies to the other derivative.

At minimum, normalize:

• exact chemical identity and CAS number;
• whether the number is percent w/w of neat active, percent w/w of a formulated blend or concentration in a test vehicle;
• assay basis and actual active contribution;
• product architecture, including water-rich serum, emulsion, anhydrous system or delivery carrier;
• exposure design, endpoint and duration if a performance claim is being considered.

For a blend, calculate active contribution rather than copying the blend use level. The calculation prevents a basic dosing error; it does not establish equivalence to neat 4HR.

What Social Users Ask and How a Professional Buyer Should Translate It

Commercial Sourcing Note

One product-level sourcing candidate is listed for this article (4BR). No 4HR offer is forced into the page without a separately screened candidate. The link is a sourcing lead, not evidence that the product is equivalent to research material or suitable for a finished cosmetic formula.

A Practical Qualification Protocol for a New Derivative

If a brand is deciding between the two ingredients, use a matched development screen where technically appropriate. Keep the same base formula, package type, mixing order and test duration. Change only the active system and record the actual active contribution. The screen should include appearance, color, pH, viscosity, assay or marker recovery, accelerated and room-temperature stability and a defined skin-tolerance plan. If the products are intended for different architectures, document that difference rather than pretending the comparison is controlled.

• Identity gate: CAS, INCI or chemical name, molecular weight, SDS and lot-specific COA agree.
• Analytical gate: the assay method is appropriate for the derivative and reports the current lot.
• Formulation gate: the material remains uniform through addition, cooling, pH adjustment and packaging.
• Performance gate: the claim is tied to the tested formula, endpoint and duration.
• Supply gate: sample, production lot, packaging and change-control expectations are documented.

Decision Rule

Choose 4BR when the project benefits from its more directly documented pigment-focused evidence and the team can qualify its solubility, stability and tolerance in the intended format. Consider 4HR only when there is a specific product rationale, compound-specific evidence and a supplier package that supports the target formula.

If the decision is being made solely because one name sounds stronger, or because one supplier lists a convenient use percentage, the qualification process has not started yet. The practical endpoint is a documented go/no-go decision: which identity is being purchased, what evidence supports the intended claim, which formulation risks remain open and what must be confirmed in the next lot.

References

1. PubChem. 4-Butylresorcinol, CID 205912. https://pubchem.ncbi.nlm.nih.gov/compound/205912
2. PubChem. Hexylresorcinol, CID 3610. https://pubchem.ncbi.nlm.nih.gov/compound/3610
3. Kolbe L, et al. 4-n-butylresorcinol and topical treatment of hyperpigmentation. https://pubmed.ncbi.nlm.nih.gov/23205541/
4. Huh SY, et al. The efficacy and safety of 4-n-butylresorcinol 0.1% cream for melasma. https://pubmed.ncbi.nlm.nih.gov/20548876/
5. Shao W, et al. Enhanced stability and reduced irritation of 4-n-butylresorcinol via nanoemulsion formulation. https://pubmed.ncbi.nlm.nih.gov/39326268/
6. Antidermatophytic action of resorcinol derivatives. https://pmc.ncbi.nlm.nih.gov/articles/PMC6274034/